Contact
Please use this form to send email to PR contact of this press release:
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
TO:
Please use this form to send email to PR contact of this press release:
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
TO: